Literature DB >> 15886627

Cochlear implantation in patients with osteogenesis imperfecta.

Sven-Olrik Streubel1, L R Lustig.   

Abstract

OBJECTIVE: Hearing loss has been shown to occur in 42% to 58% of patients with osteogenesis imperfecta (OI), with deafness arising in 25% to 60% of the patients. Implantation in patients with OI is relatively rare, with only 4 prior single case reports published in the English-language literature. The goal of this study was to evaluate the feasibility and functional outcome of cochlear implantation in 2 patients with OI tarda type I with profound sensorineural hearing loss. STUDY
DESIGN: Case series.
SETTING: The implantations were performed in a tertiary academic referral center (Johns Hopkins University).
RESULTS: Though promontory vascularity was encountered, full insertion of a normal cochlear implant array could be achieved in both cases. One-year postimplant scores demonstrated 20 to 40 dB hearing thresholds, Consonant-Nucleus-Consonant Test word scores of 54% and 70%, Consonant-Nucleus-Consonant Test phoneme scores of 75% and 83%, Hearing in Noise Test scores of 76% and 99%, and Central Institute of the Deaf Sentence Score sentence scores of 99% and 100%, for patients 1 and 2, respectively.
CONCLUSIONS: Cochlear implantation in patients with OI is not only technically possible but the results are similar to implant outcomes for patients with sensorineural hearing loss from a variety of other causes. EBM RATING: C.

Entities:  

Mesh:

Year:  2005        PMID: 15886627     DOI: 10.1016/j.otohns.2004.12.012

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  2 in total

1.  Treatments for hearing loss in osteogenesis imperfecta: a systematic review and meta-analysis on their efficacy.

Authors:  Maialen Ugarteburu; Luis Cardoso; Claus-Peter Richter; Alessandra Carriero
Journal:  Sci Rep       Date:  2022-10-12       Impact factor: 4.996

2.  Hearing loss in osteogenesis imperfecta: characteristics and treatment considerations.

Authors:  Joseph P Pillion; David Vernick; Jay Shapiro
Journal:  Genet Res Int       Date:  2011-12-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.